Natalizumab therapy for patients with multiple sclerosis (MS) has been associated with both improved clinical outcomes and an increased incidence of progressive multifocal leukoencephalopathy (PML). We provide details of the etiology and recent history of PML as associated with immunosuppressive disease states, including MS. Furthermore, it offers clinical guidance on differentiating PML from a MS relapse and a review of the current treatment options for patients suspected of having developed the complication.
KentSJ, KarlikSJ, CannonC.A monoclonal antibody to alpha 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol1995; 58: 1–10.
2.
DeloireMS, TouilT, BrochetB, DoussetV, CailleJM, PetryKG.Macrophage brain infiltration in experimental autoimmune encephalomyelitis is not completely compromised by suppressed T-cell invasion: in vivo magnetic resonance imaging illustration in effective anti-VLA-4 antibody treatment. Mult Scler2004; 10: 540–548.
3.
RiceGP, HartungHP, CalabresiPA.Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology2005; 64: 1336–1342.
4.
MillerDH, KhanOA, SheremataWA.A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2003; 348: 15–23.
5.
O'ConnorPW, GoodmanA, Willmer-HulmeAJ.Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology2004; 62: 2038–2043.
6.
O'ConnorP, MillerD, RiesterK.Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Mult Scler2005; 11: 568–572.
7.
PolmanCH, O'ConnorPW, HavrdovaE.A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
8.
RudickRA, StuartWH, CalabresiPA.Natalizumab plus interferon beta-la for relapsing multiple sclerosis. N Engl J Med2006; 354: 911–923.
9.
Kleinschmidt-DeMastersBK, TylerKL.Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-la for multiple sclerosis. N Engl J Med2005; 353: 369–374.
10.
Langer-GouldA, AtlasSW, GreenAJ, BollenAW, PelletierD.Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med2005; 353: 375–381.
11.
VanAG, VanRM, SciotR.Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med2005; 353: 362–368.
12.
HallervodenJ.Eigenartige und nicht rubrizierbare pro-zesse. In: Handbuch der Geisteskrankheiten Die Anatomie der Psychosen.Berlin: Springer, 1930, pp. 1036–1107.
13.
WinklemanNW.Lymphogranulomatosis (Hodgkin's disease) of the nervous system. Arch Neurol Psychiatry1941; 45: 304–318.
Zu RheinGM.Polyoma-like virions in a human demyelinating disease. Acta Neuropathol1967; 8: 57–68.
16.
PadgettBL, WalkerDL, ZuRheinGM, EckroadeRJ, DesselBH.Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet1971; 1: 1257–1260.
17.
PadgettBL, WalkerDL.Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis1973; 127: 467–470.
18.
BrownP, TsaiT, GajdusekDC.Seroepidemiology of human papovaviruses. Discovery of virgin populations and some unusual patterns of antibody prevalence among remote peoples of the world. Am J Epidemiol1975; 102: 331–340.
19.
WalkerBL.The epidemiology of human polyomaviruses. In: SeverJL (ed.) Polyomaviruses and human neurological diseases.New York: Alan R. Liss, 1983, pp. 99–106.
KnowlesWA.Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV). Adv Exp Med Biol2006; 577: 19–45.
22.
HouffSA, MajorEO, KatzDA.Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med1988; 318: 301–305.
23.
HoganTF, BordenEC, McBainJA, PadgettBL, WalkerDL.Human Polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med1980; 92: 373–378.
24.
HoganTF, PadgettBL, WalkerDL, BordenEC, McBainJA.Rapid detection and identification of JC virus and BK virus in human urine by using immunofluorescence microscopy. J Clin Microbiol1980; 11: 178–183.
25.
KatoA, KitamuraT, TakasakaT.Detection of the archetypal regulatory region of JC virus from the tonsil tissue of patients with tonsillitis and tonsilar hypertrophy. J Neurovirol2004; 10: 244–249.
26.
MonacoMC, AtwoodWJ, GravellM, TornatoreCS, MajorEO.JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol1996; 70: 7004–7012.
27.
MonacoMC, JensenPN, HouJ, DurhamLC, MajorEO.Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection. J Virol1998; 72: 9918–9923.
28.
MonacoMC, ShinJ, MajorEO.JC virus infection in cells from lymphoid tissue. Dev Biol Stand1998; 94: 115–122.
29.
EngPM, TurnbullBR, CookSF, DavidsonJE, KurthT, SeegerJD.Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population. Neurology2006; 67: 884–886.
30.
San-AndresFJ, RubioR, CastillaJ.Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1115 patients infected with human immunodeficiency virus, 1989-1997. Clin Infect Dis2003; 36: 1177–1185.
31.
TornatoreC, BergerJR, HouffSA.Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann Neurol1992; 31: 454–462.
32.
AzziA, De SantisR, CiappiS.Human polyomaviruses DNA detection in peripheral blood leukocytes from immunocompetent and immunocompromised individuals. J Neurovirol1996; 2: 411–416.
33.
DegenerAM, PietropaoloV, Di TarantoC.Detection of JC and BK viral genome in specimens of HIV-1 infected subjects. New Microbiol1997; 20: 115–122.
34.
DuboisV, MoretH, LafonME.Prevalence of JC virus viraemia in HIV-infected patients with or without neurological disorders: a prospective study. J Neurovirol1998; 4: 539–544.
35.
ItoyamaY, WebsterHD, SternbergerNH.Distribution of papovavirus, myelin-associated glycoprotein, and myelin basic protein in progressive multifocal leukoencephalopathy lesions. Ann Neurol1982; 11: 396–407.
BergerJR, KaszovitzB, PostMJ, DickinsonG.Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med1987; 107: 78–87.
39.
BergerJR, PallL, LanskaD, WhitemanM.Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol1998; 4: 59–68.
40.
BerenguerJ, MirallesP, ArrizabalagaJ.Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis2003; 36: 1047–1052.
41.
BergerJR, ConchaM.Progressive multifocal leukoencephalopathy: the evolution of a disease once considered rare. J Neurovirol1995; 1: 5–18.
42.
FongIW, TomaE.The natural history of progressive multifocal leukoencephalopathy in patients with AIDS. Canadian PML Study Group. Clin Infect Dis1995; 20: 1305–1310.
43.
GillespieSM, ChangY, LempG.Progressive multifocal leukoencephalopathy in persons infected with human immunodeficiency virus, San Francisco, 1981-1989. Ann Neurol1991; 30: 597–604.
44.
KapposL, BatesD, HartungHP.Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol2007; 6: 431–441.
45.
HammarinAL, BogdanovicG, SvedhemV, PirskanenR, MorfeldtL, GrandienM.Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy. J Clin Microbiol1996; 34: 2929–2932.
46.
WeberT, TurnerRW, FryeS.Progressive multifocal leukoencephalopathy diagnosed by amplification of JC virus-specific DNA from cerebrospinal fluid. AIDS1994; 8: 49–57.
47.
WeberT, TurnerRW, FryeS.Specific diagnosis of progressive multifocal leukoencephalopathy by polymerase chain reaction. J Infect Dis1994; 169: 1138–1141.
48.
BossolascoS, CaloriG, MorettiF.Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis2005; 40: 738–744.
49.
MarzocchettiA, Di GiambenedettoS, CingolaniA, AmmassariA, CaudaR, De LucaA.Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol2005; 43: 4175–4177.
50.
Case records of the Massachusetts General Hospital.Weekly clinicopathological exercises. Case 45-1988. A 67-year-old woman with chronic lymphocytic leukemia, homonymous hemianopia, confusion, and poor balance. N Engl J Med1988; 319: 1268–1280.
51.
AksamitAJ, MajorEO, GhatakNR, SidhuGS, ParisiJE, GuccionJG.Diagnosis of progressive multifocal leukoencephalopathy by brain biopsy with biotin labeled DNA : DNA in situ hybridization. J Neuropathol Exp Neurol1987; 46: 556–566.
52.
BudkaSK.Papovavirus antigens in paraffin section of PML brains. In: SeverJL (ed.) Polyomaviruses and human neurological diseases.New York: Alan R. Liss, 1983, pp. 299–309.
53.
Perez-LizG, Del VallaL, GentilellaA, CroulS, KhaliliK.Detection of JC virus DNA fragments but not proteins in normal brain tissue. Ann Neurol2008; 64: 379–387.
54.
De LucaA, GiancolaML, AmmassariA.The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis2000; 182: 1077–1083.
55.
GiudiciB, VazB, BossolascoS.Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis2000; 30: 95–99.
56.
YiannoutsosCT, MajorEO, CurfmanB.Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol1999; 45: 816–821.
57.
KhannaN, ElziL, MuellerNJ.Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis2009; 48: 1459–1466.
KhatriBO, ManS, GiovannoniG.Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology2009; 72: 402–409.
60.
CinqueP, BossolascoS, BrambillaAM.The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol2003; 9(Suppl 1): 73–80.
61.
CollazosJ, MayoJ, MartinezE, BlancoMS.Contrast-enhancing progressive multifocal leukoencephalopathy as an immune reconstitution event in AIDS patients. AIDS1999; 13: 1426–1468.
62.
D'AmicoR, SarkarS, YusuffJ, AzarE, PerlmanDC.Immune reconstitution after potent antiretroviral therapy in AIDS patients with progressive multifocal leukoencephalopathy. Scand J Infect Dis2007; 39: 347–350.
63.
GrayF, BazilleC, Adle-BiassetteH, MikolJ, MoulignierA, ScaravilliF.Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol2005; 11(Suppl 3): 16–22.
64.
HoffmannC, HorstHA, AlbrechtH, SchloteW.Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry2003; 74: 1142–1144.
65.
NuttallJJ, WilmshurstJM, NdondoAP.Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: a case of immune reconstitution inflammatory syndrome. Pediatr Infect Dis J2004; 23: 683–685.
TanK, RodaR, OstrowL, McArthurJ, NathA.PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology2009; 72: 1458–1464.
68.
TravisJ, VarmaA, duPlessisD, TurnbullI, VilarFJ.Immune reconstitution associated with progressive multifocal leukoencephalopathy in human immunodeficiency virus: a case discussion and review of the literature. Neurologist2008; 14: 321–326.
69.
VenkataramanaA, PardoCA, McArthurJC.Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology2006; 67: 383–388.
70.
LeshoE.Evidence base for using corticosteroids to treat HIV-associated immune reconstitution syndrome. Expert Rev Anti Infect Ther2006; 4: 469–478.
71.
MartinezJV, MazziottiJV, EfronED.Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology2006; 67: 1692–1694.
72.
VulliemozS, Lurati-RuizF, BorruatFX.Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry2006; 77: 1079–1082.
73.
VermaS, CikurelK, KoralnikIJ.Mirtazapine in progressive multifocal leukoencephalopathy associated with polycythemia vera. J Infect Dis2007; 196: 709–711.
74.
CettomaiD, McArthurJC.Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol2009; 66: 255–258.
75.
LanzafameM, FerrariS, LattuadaE.Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy. Infez Med2009; 17: 35–37.
76.
Vollmer-HaaseJ, YoungP, RingelsteinEB.Efficacy of camptothecin in progressive multifocal leucoencephalopathy. Lancet1997; 349: 1366.
77.
O'ReillyS.Efficacy of camptothecin in progressive multifocal leucoencephalopathy. Lancet1997; 350: 291.
78.
RoyalWIII, DupontB, McGuireD.Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol2003; 9: 411–419.
79.
BuckanovichRJ, LiuG, StriekerC.Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathy. Ann Hematol2002; 81: 410–413.
80.
KunschnerL, ScottTF.Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. Neurology2005; 65: 1510.
81.
PrzepiorkaD, JaeckleKA, BirdwellRR.Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2. Bone Marrow Transplant1997; 20: 983–987.
82.
GeschwindMD, SkolaskyRI, RoyalWS, McArthurJC.The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. J Neurovirol2001; 7: 353–357.
83.
TantisiriwatW, TebasP, CliffordDB, PowderlyWG, FichtenbaumCJ.Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis1999; 28: 1152–1154.
84.
HuangSS, SkolaskyRL, Dal PanGJ, RoyalWIII, McArthurJC.Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. J Neurovirol1998; 4: 324–332.
85.
AlbrechtH, HoffmannC, DegenO.Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS1998; 12: 1149–1154.
ColosimoC, LebonP, MartelliM, TumminelliF, MandelliF.Alpha-interferon therapy in a case of probable progressive multifocal leukoencephalopathy. Acta Neurol Belg1992; 92: 24–29.
88.
KraemerC, EversS, NoltingT, ArendtG, HusstedtIW.Cidofovir in combination with HAART and survival in AIDS-associated progressive multifocal leukoencephalopathy. J Neurol2008; 255: 526–531.
89.
De LucaA, AmmassariA, PezzottiP.Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS2008; 22: 1759–1767.
90.
ViallardJF, LazaroE, EllieE.Improvement of progressive multifocal leukoencephalopathy after cidofovir therapy in a patient with a destructive polyarthritis. Infection2007; 35: 33–36.
91.
TorgovnickJ, SethiN, KarterD, ArsuraE.Remission of AIDS-associated progressive multifocal leukoencephalopathy with combined cidofovir and radiotherapy: a case report. AIDS2006; 20: 1569–1570.
92.
Herrero-RomeroM, CorderoE, Lopez-CortesLF, de AlarconA, PachonJ.Cidofovir added to highly active antiretroviral therapy in AIDS-associated progressive multifocal leukoencephalopathy. AIDS2001; 15: 809.
93.
CardenasRL, ChengKH, SackK.The effects of cidofovir on progressive multifocal leukoencephalopathy: an MRI case study. Neuroradiology2001; 43: 379–382.
94.
ZimmermannT, StingeleK, HartmannM, HaasJ, von EinsiedelR, WildemannB.Successful treatment of aids related PML with HAART and cidofovir. Eur J Med Res2001; 6: 190–192.
95.
De LucaA, GiancolaML, AmmassariA.Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study. J Neurovirol2001; 7: 364–8.
96.
ChocarroMA, GonzalezLA, GarciaGI.Successful resolution of progressive multifocal leukoencephalopathy after combination therapy with cidofovir and cytosine arabinoside. Clin Infect Dis2000; 30: 234.
97.
MarraCM, RajicicN, BarkerDE.A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS2002; 16: 1791–1797.
98.
TubridyN, WellsC, LewisD, SchonF.Unsuccessful treatment with cidofovir and cytarabine in progressive multifocal leukoencephalopathy associated with dermatomyositis. J R Soc Med2000; 93: 374–375.
99.
BlickG, WhitesideM, GriegorP, HopkinsU, GartonT, LaGravineseL.Successful resolution of progressive multifocal leukoencephalopathy after combination therapy with cidofovir and cytosine arabinoside. Clin Infect Dis1998; 26: 191–192.
100.
O'BrienMD, HonavarM.Progressive multifocal leucoencephalopathy treated with cytosine arabinoside: 12 year follow up and postmortem findings. J Neurol Neurosurg Psychiatry1997; 62: 427–428.
101.
AntinoriA, De LucaA, AmmassariA.Failure of cytarabine and increased JC virus-DNA burden in the cerebrospinal fluid of patients with AIDS-related progressive multifocal leucoencephalopathy. AIDS1994; 8: 1022–1024.
102.
SteigerM J, TarnesbyG, GabeS, McLaughlinJ, SchapiraAH.Successful outcome of progressive multifocal leukoencephalopathy with cytarabine and interferon. Ann Neurol1993; 33: 407–411.
103.
de TruchisP, Flament-SaillourM, UrtizbereaJA, HassineD, ClairB.Inefficacy of cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet1993; 342: 622–623.
104.
PortegiesP, AlgraPR, HollakCE.Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet1991; 337: 680–681.
BauerWR, TurelAPJr, JohnsonKP.Progressive multifocal leukoencephalopathy and cytarabine. Remission with treatment. JAMA1973; 226: 174–176.
107.
HallCD, DafniU, SimpsonD.Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med1998; 338: 1345–1351.
108.
YousryTA, MajorEO, RyschkewitschC.Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. iV Engl J Med2006; 354: 924–933.
109.
HydeR, BozicC, BelcherG, Dong-SiT, KimR, LynnF, Kooijans-CoutinhoM, PanzaraMA.Utilization and safety of natalizumab in patients with relapsing multiple sclerosis in the post-marketing setting. World Congress of Neurology, FP33-WE-04, 28 October 2009.
ArthurRR, ShahKV.Occurrence and significance of papovaviruses BK and JC in the urine. Prog Med Virol1989; 36: 42–61.
112.
KoralnikIJ, BodenD, MaiVX, LordCI, LetvinNL.JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology1999; 52: 253–260.
113.
MajorEO, YousryTA, CliffordDB.Natalizumab for relapsing multiple sclerosis. iV Engl J Med2006; 354: 2388–2389.
